# A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients

> **NCT02000609** · PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 49 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** CHF 1535 NEXThaler 800/48
- **DRUG:** CHF 1535 NEXThaler 200/12
- **DRUG:** CHF 1535 NEXThaler PLACEBO
- **DRUG:** CHF 1535 pMDI 200/12
- **DRUG:** CHF1535 pMDI 800/48

## Key facts

- **NCT ID:** NCT02000609
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02000609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02000609, "A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02000609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*